Literature DB >> 2601257

Acute cyclosporine renal dysfunction reversed by dopamine infusion in healthy subjects.

G Conte1, A Dal Canton, M Sabbatini, P Napodano, L De Nicola, G Gigliotti, G Fuiano, A Testa, C Esposito, D Russo.   

Abstract

Up to now, no studies have been performed in normal humans to investigate the role of renal hemodynamic abnormalities in relation to acute-cyclosporin A (CsA) renal dysfunction and to verify whether the specific renal vasodilator, dopamine, can counteract these abnormalities. Eight normal subjects were examined both (A) after oral CsA (12 mg/kg body wt) and (B) after oral CsA + dopamine infusion (2 mg/kg body wt/min), under water diuresis. Both in protocols A and in B, four basal renal clearances were performed before CsA and every twenty minutes for four hours after CsA administration. In protocol A, after CsA, inulin (GFR) and PAH clearance (RPF) fell by up to 27% and to 41%, respectively, so that filtration fraction (FF) increased (P less than 0.01). A slight (not significant) hypertension occurred while renal resistances were markedly raised (P less than 0.001). Fractional urine and Na+ excretion as well as CH2O decreased, while UOsm increased (P less than 0.01). In protocol B, dopamine was infused from 120 to 180 minutes after CsA (that is, when the maximal adverse effects of CsA on renal hemodynamics had been observed in A). Dopamine infusion could reverse completely the effects of CsA on RPF, GFR, fractional urine output and CH2O; only UOsm remained higher than normal in conclusion with an increased fractional excretion of sodium (P less than 0.01). No changes were observed in plasma renin activity, aldosterone and in urinary epinephrine and norepinephrine excretion both in protocols.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2601257     DOI: 10.1038/ki.1989.304

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

Review 1.  Can the use of low-dose dopamine for treatment of acute renal failure be justified?

Authors:  C J Burton; C R Tomson
Journal:  Postgrad Med J       Date:  1999-05       Impact factor: 2.401

Review 2.  Is RAS blockade routinely indicated in hypertensive kidney transplant patients?

Authors:  Daniel J Salzberg
Journal:  Curr Hypertens Rep       Date:  2007-11       Impact factor: 5.369

Review 3.  Immunosuppressant-induced nephropathy: pathophysiology, incidence and management.

Authors:  A J Olyaei; A M de Mattos; W M Bennett
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

Review 4.  Transmembrane signaling in kidney health and disease.

Authors:  N Hack; A Schultz; P Clayman; H Goldberg; K L Skorecki
Journal:  Pediatr Nephrol       Date:  1995-08       Impact factor: 3.714

Review 5.  Cyclosporin-induced hypertension: incidence, pathogenesis and management.

Authors:  S J Taler; S C Textor; V J Canzanello; L Schwartz
Journal:  Drug Saf       Date:  1999-05       Impact factor: 5.606

6.  Arginine feeding modifies cyclosporine nephrotoxicity in rats.

Authors:  L De Nicola; S C Thomson; L M Wead; M R Brown; F B Gabbai
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

7.  Effects of a selective adenosine A1 receptor antagonist on the development of cyclosporin nephrotoxicity.

Authors:  V S Balakrishnan; C J von Ruhland; D F Griffiths; G A Coles; J D Williams
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

8.  Cyclosporine stimulates the renal epithelial sodium channel by elevating cholesterol.

Authors:  Jing Wang; Zhi-Ren Zhang; Chu-Fang Chou; You-You Liang; Yuchun Gu; He-Ping Ma
Journal:  Am J Physiol Renal Physiol       Date:  2008-12-17

9.  The use of diuretics and dopamine in acute renal failure: a systematic review of the evidence.

Authors: 
Journal:  Crit Care       Date:  1997       Impact factor: 9.097

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.